Business Wire

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute ...
MD&M East

Reprieve Study Holds Promise for ADHF Care

Reprieve Cardiovascular today announced results for its first-in-human study of the Reprieve system for the treatment of acute decompensated heart failure (ADHF). The study focused on the device’s ...
TCTMD

Device-Based Therapy Offers REPRIEVE From Decongestion in Acute HF: TARGET 1 and 2

ATHENS, Greece—A device-based fluid-management system that regulates decongestion in conjunction with diuretic therapy appears safe and is able to successfully control fluid loss in patients ...
TCTMD

REPRIEVE Stopped: Big MACE Reductions With Statins in HIV+ Subjects

A daily statin can reduce the risk of new-onset cardiovascular disease in people living with HIV, according to preliminary results from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE ...
Yahoo Finance

Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial

-- Late-Breaking Clinical Data Presented at the Technology and Heart Failure Therapeutics (THT) Annual Meeting Demonstrates Safety and Efficacy of the Reprieve System Compared to Optimal Diuretic ...
Business Wire

Reprieve Cardiovascular Builds Clinical Momentum with Positive Results from FASTR Pilot Trial and FDA Investigational Device Exemption Approval for Pivotal Trial

MILFORD, Mass.--(BUSINESS WIRE)--Reprieve Cardiovascular, Inc., a development-stage company focused on advancing acute decompensated heart failure (ADHF) treatment, today announced topline results ...